Arbor/Azurity Patent-Cliff Exposure & CMS Drug Spending Portfolio

Arbor/Azurity (US): 8 reconciled FDA prescription therapies, $68.6M 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$68.6M
2024 Medicare Part D Spend$63.3M
2024 Medicaid Spend$5.3M
California HCAI SB 17 Filings14 WAC filings (max 49.9% 2-yr change)